State of Oklahoma SoonerCare





Vizimpro® (Dacomitinib) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
	Drug Informatio	n
narmacy billing (NDC:) Start Date (or date of next dose):		e (or date of next dose):
Dose:Regimen:		
	Billing Provider Infor	mation
Provider NPI:	Provider Name:	
Provider Phone:	ider Phone:Provider Fax:	
	Prescriber Informa	tion
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
A. Has member recedisease? Yes B. EGFR exon 19 decomposition C. Exon 21 L858R solution D. Will dacomitinib bounded on the composition of the	' '	No
 Has the member experience If yes, please specify adverse re Additional Information: 	ence of progressive disease while or ed any adverse drug reactions relat reactions:	on dacomitinib therapy? Yes No ted to dacomitinib therapy? Yes No
Prescriber Signature		_ Date:
l continue that the indicated treatment	ant is modically passage, and all i	_ Date

I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

result in processing delays.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm-110 5/23/2023